Skip to Content
Questions about Atrial Fibrillation? Get answers from our expert.

Verapamil Pregnancy and Breastfeeding Warnings

Verapamil is also known as: Calan, Calan SR, Covera-HS, Isoptin, Isoptin IV, Isoptin SR, Verelan, Verelan PM

Verapamil Pregnancy Warnings

Verapamil has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity; however, there was evidence of embryolethality and fetotoxicity at doses which produced maternal toxicity. There are no controlled data in human pregnancy. Verapamil should only be given during pregnancy when benefit outweighs risk.

Although verapamil is known to cross the human placenta, there are no reports linking verapamil with congenital defects in human pregnancy. Verapamil has been used safely to treat maternal hypertension and both maternal and fetal tachyarrhythmias. One case in which both digoxin and verapamil were successfully used to treat fetal supraventricular tachycardia at 32 weeks gestation is reported. Four weeks after the initiation of therapy, the fetus died, presumably due to complete heart block. Autopsy results are unavailable. Other than the association of fetal abnormality in this case, no adverse fetal or neonatal effects attributable to verapamil are reported. Because of the potential of reduced uterine blood flow associated with verapamil-induced hypotension, it is recommended that intravenous verapamil be used cautiously during pregnancy if it must be used. Data from the Michigan Medicaid Birth Defects Study failed to reveal an association between verapamil and congenital abnormalities (written communication, Franz Rosa, MD, Food and Drug Administration, 1994). This was a retrospective study of 229,101 completed pregnancies between 1985 and 1992, of which 76 were exposed to verapamil at some time during the first trimester and 172 were exposed to the drug at any time during pregnancy. Of these pregnancies, one cardiovascular defect was observed. This observation did not achieve statistical significance. These data do not support an association between verapamil and birth defects. A retrospective review of 78 women with first-trimester exposure to calcium channel blockers (CCBs) (41%, or 32 were taking verapamil) revealed no increase in major malformations compared with a control group matched for maternal age and smoking. This review suggests that CCBs do not represent a major teratogenic risk.

See references

Verapamil Breastfeeding Warnings

Two case studies have shown that between 23% and 60% of the maternal serum verapamil concentration may be found in human milk at steady state. In case studies where verapamil concentration in human milk was calculated, the nursing infant doses ranged from less than 0.01% to 0.1% of the mother's dose. Possible infant exposure should be considered when verapamil is administered to a nursing woman.

Verapamil is excreted into human milk. Side effects in the nursing infant are unlikely. However, the manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Verelan PM (verapamil)." Schwarz Pharma, Mequon, WI.
  2. Brittinger WD, Schwarzbeck A, Wittenmeier KW, et al. "Clinical trial of the hypotensive effect of verapamil." Dtsch Med Wochenschr 95 (1970): 1871-7
  3. Rotmensch HH, Rotmensch S, Elkayam U "Management of cardiac arrhythmias during pregnancy: current concepts." Drugs 33 (1987): 623-33
  4. Goodnick PJ "Verapamil prophylaxis in pregnant women with bipolar disorder." Am J Psychiatry 150 (1993): 1560
  5. "Product Information. Calan (verapamil)." Searle, Skokie, IL.
  6. Wolff F, Breuker KH, Schlensker KH, Bolte A "Prenatal diagnosis and therapy of fetal heart rate anomalies: with a contribution on the placental transfer of verapamil." J Perinat Med 8 (1980): 203-8
  7. Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover E, Cook L, Mcelhatton PR, Schmidt MA, Koren G "The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study." Am J Obstet Gynecol 174 (1996): 823-8
  8. Page RL "Treatment of arrhythmias during pregnancy." Am Heart J 130 (1995): 871-6
  9. Belpaire FM, Wynant P, Vantrappen P, Dhont M, Verstraete A, Bogaert MG "Protein binding of propranolol and verapamil enantiomers in maternal and foetal serum." Br J Clin Pharmacol 39 (1995): 190-3
  10. Owen J, Colvin EV, Davis RO "Fetal death after successful conversion of fetal supraventricular tachycardia with digoxin and verapamil." Am J Obstet Gynecol 158 (1988): 1169-70

References for breastfeeding information

  1. "Product Information. Calan (verapamil)." Searle, Skokie, IL.
  2. Andersen HJ "Excretion of verapamil in human milk." Eur J Clin Pharmacol 25 (1983): 279-80
  3. Anderson P, Bondesson U, Mattiasson I, Johansson BW "Verapamil and norverapamil in plasma and breast milk during breast feeding." Eur J Clin Pharmacol 31 (1987): 625-7
  4. "Product Information. Verelan PM (verapamil)." Schwarz Pharma, Mequon, WI.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.